GuidelineHerz2015
[Diagnosis and management of acute pulmonary embolism. ESC guidelines 2014].
Guideline in Herz, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Minimally invasive spinal anesthesia for cesarean section in maternal anticoagulation therapy: a randomized controlled trial.BMC anesthesiology · 2019Trial
- Article
- Rare Case of Acute Pulmonary Thromboembolism After Internal Fixation of Multiple Rib Fractures.Clinical case reports · 2025Article
- Hospitalization for venous thromboembolic disease management: a 10 years Registry in Buenos Aires, Argentina.Journal of thrombosis and thrombolysis · 2021Article
- The Positive Rate of Pulmonary Embolism by CT Pulmonary Angiography Is High in an Emergency Department, Even in Low-Risk or Young Patients.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021Article
- D-Dimer is a strong predictor of in-hospital mortality in patients with infective endocarditis.Anatolian journal of cardiology · 2019Article
- Expression of microRNA-514a-5p and its biological function in experimental pulmonary thromboembolism.American journal of translational research · 2019Article
- The role of rivaroxaban in left ventricular thrombi.Anatolian journal of cardiology · 2019Article
- Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity.Journal of thoracic disease · 2018Review
- Fatal pulmonary embolism following splenectomy in a patient with Evan's syndrome: case report and review of the literature.Thrombosis journal · 2017Article
- Resolution of left ventricular postinfarction thrombi in patients undergoing percutaneous coronary intervention using rivaroxaban in addition to dual antiplatelet therapy.BMJ case reports · 2016Article
- Diagnostic management of inpatients with a positive D-dimer test: developing a new clinical decision-making rule for pulmonary embolism.Pulmonary circulationArticle
- Diagnostic implications of computed tomography pulmonary angiography in patients with pulmonary embolism.Annals of thoracic medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pulmonary embolism (PE) still represents a challenge regarding a rapid diagnosis and a risk-adapted therapy. In the 2014 guidelines of the European Society of Cardiology (ESC) on the diagnosis and management of acute PE, several new recommendations have been issued based on new study data. Some established scores for risk stratification were developed further and there is now good evidence for the use of age-adjusted D-dimer cut-off levels. For the risk stratification in patients without clinical features of shock, the utilization of the pulmonary embolism severity index (PESI) and simplified PESI (sPESI) scores is recommended. In patients with intermediate risk, right ventricular morphology and function can be evaluated by computer tomography or echocardiography and biomarkers facilitate further risk stratification. For the treatment of patients with venous thromboembolism with or without PE, the non-vitamin K-dependent oral anticoagulants (NOACs) are a safe alternative to the standard anticoagulation regimen with heparin and vitamin K antagonists. Systemic thrombolytic therapy should be restricted to patients with high risk or intermediate high risk with hemodynamic instability. Finally, new recommendations for the diagnosis and therapy of patients with chronic thromboembolic pulmonary hypertension (CTEPH), with cancer or during pregnancy are given.
Indexed as
Identifiers
26626553What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.